Antibodies that are capable of specifically binding tissue factor pathway inhibitor
US9228022B2 · kind B2 · utility
2Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2013 |
| Grant date | Jan 5, 2016 |
| Priority date | — |
| Expiry date | Feb 28, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.